Where does Intermune, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Intermune, Inc. ranks #18,770 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Intermune, Inc. hold?

Intermune, Inc. holds 15 US utility patents granted between 2015 and 2021, spanning 10 technology areas.

What is Intermune, Inc.'s Innovation Score?

Intermune, Inc. has an Innovation Score of 34.9 out of 100 (49th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Intermune, Inc. focus on?

Intermune, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 14 patents, ranking #1,384 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Intermune, Inc.'s patent grant rate increasing or decreasing?

Intermune, Inc.'s recent grant velocity is -85% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Intermune, Inc.'s patents?

Intermune, Inc.'s patents average 23.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Intermune, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Intermune, Inc.

USPTO PatentsView assignee record - 15 granted patents across 10 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Intermune ranks #18,770 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 10 technology areas.

#18,770
of 49,997 US assignees by volume: 49th percentile
by Innovation Score (34.9/100): 23.6
avg claims per patent: -85%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18770 · US Corporation #18,770 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,770/49,997
PHOTO-FINISH Idea Boxx
CPC-FOCUS A61P · 10 areas
INNOV-THIN 34.9/100
CLAIMS-DENSE 23.6 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -85% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Idea Boxx, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Intermune’s 34.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (27%) Velocity 0.0 pts (0%) Breadth 11.2 pts (32%) Claim depth 14.2 pts (41%)

Qualcomm Incorporated · highest

85
Intermune · this assignee

35
3D Lighting… · lowest

7

What this shows Intermune's Innovation Score is 34.9/100 (49th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Intermune?

Each dot is one of Intermune’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Intermune’s own 23.6 claims/patent is ABOVE the 13.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Intermune vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Intermune's grants concentrate

Intermune, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 93.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (4 grants) versus a trough of 1 in 2020. By volume, Intermune sits between Institut FRANÇAIS DES Sciences ET Technologies DES Transports DE L'amenagement ET DES Reseaux (IFSTTAR) and Idea Boxx, LLC.

Institut FRANÇAIS…

15
Instituto Superio…

15
Intai Technology

15
Integrated Plasti…

15
Iorthopedics

15
Ipower Semiconduc…

15
Italcementi S P A

15
Idea Boxx

15
Intermune ◀

15

What this shows Intermune holds 15 patents at rank #18,756, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Intermune

By rank, the assignees closest to #18,756 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Intermune's primary technology class.

Intermune's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 49th percentile higher than 49% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Intermune, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	13.3%
2016	3	20.0%
2017	4	26.7%
2018	2	13.3%
2019	2	13.3%
2020	1	6.7%
2021	1	6.7%

Which technologies does Intermune, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 14

C07D - Heterocyclic Compounds 12

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C07K - Peptides 2

C08F - Macromolecular Compounds Obtained BY Reactions Only Involving Carbon-to-carbon Unsaturated Bonds 2

Y02A - Technologies FOR Adaptation TO Climate Change 2

C07C - Acyclic OR Carbocyclic Compounds 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Intermune, Inc.'s patent record in context - here's where to go next.

Intermune, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 93.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #18,770 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Intermune, Inc. against Institut FRANÇAIS DES Sciences ET Technologies DES Transports DE L'amenagement ET DES Reseaux (IFSTTAR), an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.